MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 159.7 USD | +11.17% |
|
+23.61% | +60.41% |
| 05-20 | Moderna Insider Sold Shares Worth $1,909,863, According to a Recent SEC Filing | MT |
| 05-17 | Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing | MT |
| Sales 2024 * | 4.18B 328B | Sales 2025 * | 4.84B 380B | Capitalization | 55.07B 4,326B |
|---|---|---|---|---|---|
| Net income 2024 * | -2.7B -212B | Net income 2025 * | -1.97B -155B | EV / Sales 2024 * | 11.7 x |
| Net cash position 2024 * | 6.25B 491B | Net cash position 2025 * | 3.94B 310B | EV / Sales 2025 * | 10.6 x |
| P/E ratio 2024 * |
-20.3
x | P/E ratio 2025 * |
-28
x | Employees | 5,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | +10.55% | ||
| 1 week | +21.42% | ||
| Current month | +42.05% | ||
| 1 month | +50.01% | ||
| 3 months | +57.58% | ||
| 6 months | +100.46% | ||
| Current year | +57.57% |
1 week
127.83
156.99
1 month
103.48156.99
Current year
84.06156.99
1 year
62.55156.99
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 28/02/11 |
James Mock
DFI | Director of Finance/CFO | 47 | 05/09/22 |
Stephen Hoge
PSD | President | 48 | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 31/05/18 |
| Director/Board Member | 74 | 30/06/20 | |
Francois Nader
BRD | Director/Board Member | 67 | 10/12/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/05/24 | 159.7 | +11.16% | 7 491 389 |
| 21/05/24 | 143.7 | +1.90% | 3,375,932 |
| 20/05/24 | 141 | +6.10% | 4,711,331 |
| 17/05/24 | 132.9 | +0.17% | 2,718,168 |
| 16/05/24 | 132.7 | +2.80% | 3,008,046 |
Delayed Quote Nasdaq, May 22, 2024 at 03:44 pm
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
31/05/2024
- Bernstein Strategic Decisions Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
143.7
USD
Average target price
138.5
USD
Spread / Average Target
-3.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.57% | 55.07B | |
| -1.92% | 41.79B | |
| +44.42% | 40.22B | |
| -7.59% | 28.17B | |
| +12.00% | 26.28B | |
| -21.03% | 18.93B | |
| +7.10% | 13.03B | |
| +29.02% | 12.26B | |
| +25.91% | 12.21B | |
| -7.13% | 11.41B |
- Stock Market
- Equities
- MRNA Stock
